Investors
Share price
{{priceData.date}} {{priceData.time}}
{{'2025-01-24T10:19:59Z' | dateFormatFilter}}
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Read more
{{'2025-01-17T12:11:58Z' | dateFormatFilter}}
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Read more
{{'2025-01-08T11:30:49Z' | dateFormatFilter}}
Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases
Read more
Here are our current job openings. If there is not a job you are looking for, you are welcome to create a job agent or a candidate profile.